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Abstract: The blending of synthetic chemistry with biosyn-
thetic processes provides a powerful approach to synthesis.
Biosynthetic halogenation and synthetic cross-coupling have
great potential to be used together, for small molecule gen-
eration, access to natural product analogues and as a tool
for chemical biology. However, to enable enhanced generali-
ty of this approach, further synthetic tools are needed.
Though considerable research has been invested in the di-
versification of phenylalanine and tyrosine, functionalisation
of tryptophans thorough cross-coupling has been largely ne-
glected. Tryptophan is a key residue in many biologically
active natural products and peptides; in proteins it is key to
fluorescence and dominates protein folding. To this end, we
have explored the Heck cross-coupling of halo-indoles and
halo-tryptophans in water, showing broad reaction scope.
We have demonstrated the ability to use this methodology
in the functionalisation of a brominated antibiotic (bromo-
pacidamycin), as well as a marine sponge metabolite, bare-
ttin.
Introduction
Tryptophan is a key residue in many biologically active natural
products, peptides and proteins.[1, 2] Its intrinsic fluorescence
dominates the spectrophotometric properties of a given pep-
tide or protein; it is a crucial residue for stabilising secondary
and tertiary structure through intra and intermolecular interac-
tions.[3] Tryptophan residues have been shown to play a central
role in protein folding[4] as well as being implicated in govern-
ing the function of many biologically important systems in-
cluding mechanosensitive channels within the membrane.[5]
The possibility of functionalising tryptophan in order to modify
this important residue both sterically and electronically would
be exciting and potentially afford a means of interrogating,
modulating and tuning the properties of peptides, proteins
and natural products.
Though considerable research has been carried out on selec-
tive modification of halogenated phenylalanines and tyro-
sines[7] through the application of cross-coupling chemistry,
the functionalisation of tryptophan has, until recently, re-
mained largely unexplored.[6] One potential reason for this is
the challenge that such metal mediated cross-coupling reac-
tions present with tryptophan; indeed, tryptophan has been
demonstrated to poison the Suzuki–Miyaura cross-coupling of
halo-indoles.[8] This may be attributed to the amino acid coor-
dinating to the palladium catalyst.[9] Notably, esterification of
the carboxylate and acylation of the primary amine reduces re-
action poisoning, however even this species is not fully inno-
cent and its incorporation in a reaction is still seen to impact
upon conversion.[8]
In recent years, series of studies enabling the cross-coupling
of halo-tryptophans through application of Suzuki–Miyaura
and Sonogashira chemistries in aqueous media have been re-
ported.[6–8] Combination of these chemistries with enzymatic
halogenation has been used powerfully for selective CH acti-
vation and diversification of small molecules[10] The application
of Heck cross-coupling would provide a valuable addition to
this growing portfolio of reactions for tryptophan functionali-
sation, enabling the potential for extension of conjugation and
[a] Dr. C. Pubill-Ulldemolins,+ Dr. S. V. Sharma,+ C. Cartmell,+ Dr. J. Zhao,
Prof. R. J. M. Goss
Department of Chemistry and BSRC
University of St Andrews
St Andrews, KY16 9ST (UK)
E-mail : rjmg@st-andrews.ac.uk
[b] Dr. C. Pubill-Ulldemolins+
Present address: Department of Chemistry
School of Life Sciences
University of Sussex
Brighton, BN19QJ (UK)
[c] P. Crdenas
Pharmacognosy, Department of Medicinal Chemistry
Uppsala University
Uppsala 75123 (Sweden)
[+] These authors contributed equally to this work.
Supporting information and the ORCID identification number(s) for the au-
thor(s) of this article can be found under:
https://doi.org/10.1002/chem.201901327.
 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.
This is an open access article under the terms of the Creative Commons At-
tribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
Chem. Eur. J. 2019, 25, 1 – 11  2019 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim1 &&
These are not the final page numbers! 
Full PaperDOI: 10.1002/chem.201901327
tuning of electronic and fluorescence properties as well as the
opportunity to potentially modulate conformations of small
molecules, peptides and proteins.
Heck cross-coupling methodologies have been effectively
applied to series of other biomolecules including nucleo-
sides,[11] nucleotides and nucleoside triphosphates.[12] However,
there are very few studies reported of the utilisation of Heck
methodologies for the modification of amino acids, and pep-
tides, mostly utilising highly activated (iodo or triflate) sub-
strates. These include modification of N- and C-protected 3,5-
di-iodo-l-tyrosine, modulating and extending its conjugation
and enabling its fluorescence properties to be tuned, and di-
versification of N- and C-protected l-tyrosine para-triflate,[13]
and selective modification of 4-iodo-l-phenylalanine within a
small protein, using Mizoroki–Heck conditions.[14]
Whilst this manuscript was being prepared, the first
Mizoroki–Heck coupling of a halo-tryptophan was reported. In
this study free, unprotected 7-bromo-tryptophan was deriva-
tised with 6 different styrenes.[15] Excitingly, as observed with
the Suzuki–Miyaura cross-coupling of tryptophan,[6a,8] these
tryptophan-7-styrene products were shown to be fluorogenic,
thus again opening up the way for fluorescence modulation of
halo-tryptophans. There is considerable potential for the devel-
opment of Heck methodologies for the functionalisation of
free and biomolecule embedded halo-tryptophans. Herein, we
report our exploration of the systematic application of the
Heck reaction first to halo-indoles, then to free and unprotect-
ed halo-tryptophans. We then move on to challenge the devel-
oped methodology, applying it to unprotected and complex
natural product barettin as well as natural product derivative
bromo-pacidamycin and to a range of aliphatic and aromatic
alkenes (Scheme 1).
Results and Discussion
Moore and Shaughnessy first exemplified the use of aqueous
phase Heck coupling of aryl bromides using the sterically de-
manding tri-(4,6-dimethyl-3-sulphonatophenyl)phosphine triso-
dium salt (TXPTS) as ligand to enable water solubilisation of
the Pd(OAc)2. Their mild aqueous conditions, using Na2CO3 as
base enabled modification of aryl iodides and bromides in
high yield (79–94%).[16] Starting with their reported conditions,
we explored whether these could be utilised to enable Heck
modification of reactive 5-iodo-indole 1 with acrylic acid 2. By
heating for 18 h using Na2PdCl4-TXPTS as the catalyst gave a
conversion to 51% and an isolated yield of 43% (Table 1).
To improve these results, we next explored the impact of
varying the catalyst, (investigating water-soluble Na2PdCl4) in
Table 1. Initial Heck cross-coupling conditions explored for 5-I-indole
with acrylic acid.
Entry X Pd/Ligand t [h] Conv. [%][a,b] Yield [%][c]
1 5-I 1 Pd(OAc)2/TXPTS 2 18 –
2 5-I 1 Pd(OAc)2/TXPTS 18 32 –
3 5-I 1 Na2PdCl4/TXPTS 18 51 43
Reaction conditions: [a] 5-I-indole (0.1 mmol), acrylic acid (1.5 equiv,
0.15 mmol), Pd salt (2.5 mol%), TXPTS (6.25 mol%), Na2CO3 (2.0 equiv,
0.2 mmol), CH3CN/H2O (1:1, 1 mL), conventional heating, reflux, solids and
solvents purged with argon. [b] Based on ratio of starting material aro-
matic peak at dH 6.40 ppm compared to product aromatic peak at dH
6.50 ppm in CD3OD. [c] Isolated yields are reported after flash chromatog-
raphy.
Scheme 1. Heck cross-coupling under aqueous conditions applied to bio-
molecules: all relevant prior work is outlined along with work within this
study. (A) Shaughnessy’s initial aqueous Heck cross-coupling.[16] (B) Tagging
of 4-iodo-L-phenylalanine within a small protein.[14] (C) Heck modification of
iodinated nucleoside triphosphates.[12, 13] (D) Reported Heck modification of
7-bromo-tryptophan with styrenes.[15] (E), (F) Heck modification of a series of
indoles and tryptophans, respectively. (G) and (H) Heck modification of the
antibiotics barettin and pacidamycin, respectively.
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combination with exploring the application of the sterically
more demanding and electron-rich ligand SSPhos, designed by
Buchwald.[17] Microwave heating was also explored (Table 2).
These studies revealed that by using SSPhos in place of
TXPTS gave a modest increase in conversion of 5-iodo-indole 1
(78–85%, Table 2, entries 1 and 2). A significant increase in
conversion (97%) could be seen upon replacing Pd(OAc)2 with
Na2PdCl4 (Table 2, entry 3). By replacing conventional heating
with microwave heating, >99% conversion could be achieved
after only one hour. Notably, for 5-iodo-indole 1, it was possi-
ble to achieve almost quantitative conversion using microwave
heating and in the absence of an additional ligand (Table 2,
entry 5). Next, we set out to explore the Heck modification of
the less reactive 5-bromo-indole 4. Here, we observed conver-
sions to be far more modest in the absence of any ligand,
however utilisation of SSPhos again enabled almost quantita-
tive conversions (Table 2, entry 8).
With these conditions in hand, we next set out to explore
whether we could proceed past acrylic acid 2 as the coupling
partner. The conditions that we had developed showed good
applicability enabling the Heck modification of both 5-iodo 1
and 5-bromo-indole 4 to proceed almost quantitatively with a
range of different alkene cross-coupling partners (Table 3).
The only exception to this rule was styrene 11 (Table 3,
entry 6) because of the reduced reactivity of this species aris-
ing due to the electron rich nature of the alkene. Also, for this
reason, nonactivated 1-octene and cyclohexene gave no con-
version under the same reaction conditions. From NMR charac-
terisation of the products it may be seen that all Heck coupling
reactions progressed with a high level of stereoselectivity to
generate only the E-isomers. The trans-relation of the double
bonds was established on the basis of the coupling constant
for the vinylic protons in the 1H NMR spectra (J=16 Hz, see
Supporting Information).
Having achieved a system that would work well for the func-
tionalisation of iodo- and bromo-indoles 1 and 4, we next set
out to explore whether it might be possible to extend this
methodology further to the aqueous cross-coupling of the far
more challenging free, unprotected halo-tryptophans.
Halo-tryptophans may be readily accessed through a simple
one-step biotransformation using tryptophan synthase,[18,19] or
through a 4–5 step chemical synthesis.[20] Challenges that need
to be addressed to render Heck cross-coupling of free halo-
tryptophans useful are their poor solubility and their propensi-
ty to chelate to and deactivate the palladium catalyst.[9]
Utilisation of our previous conditions that had been opti-
mised for the aqueous Heck cross-coupling of halo-indoles
with acrylic acid resulted in almost no observable conversion
of 5-bromo-tryptophan 19 even at 100 8C (Table 4, entries 1
and 2), we therefore returned to exploration of both TXPTS
and TPPTS as water soluble ligands with the highly reactive
7-iodo-tryptophan 20. By doubling both the amount of cata-
lyst and ligand, it was possible to achieve almost quantitative
conversion using either TPPTS or TXPTS when heated to 90 8C,
though with TPPTS an extended reaction time of 2 h was re-
quired (Table 4, entries 3–6). Applying these conditions, using
TPPTS to the less reactive 7-bromo-tryptophan 21, a conver-
sion of only 47% is observed (Table 4, entry 7). However, by
switching to the more sterically demanding TXPTS ligand,
almost quantitative conversion was achieved (Table 4, entry 8).
As the 5 and 6-halo-tryptophans are more reactive than the 4
and 7-counterparts, the sterically less demanding TPPTS was
Table 2. Optimization of the reaction conditions.
Entry X Pd/Ligand T t [h] Conv. [%][a,b] Yield [%][c]
1 5-I 1 Pd(OAc)2/TXPTS reflux 18 78 67
2 5-I 1 Pd(OAc)2/
sSPhos reflux 18 85 73
3 5-I 1 Na2PdCl4/
sSPhos reflux 18 97 86
4 5-I 1 Na2PdCl4/
sSPhos MW 1 >99 90
5 5-I 1 Na2PdCl4/none MW 1 >99 89
6 5-Br 4 Na2PdCl4/none MW 1 48 36
7 5-Br 4 Na2PdCl4/TXPTS MW 1 77 65
8 5-Br 4 Na2PdCl4/
sSPhos MW 1 >99 94
Reaction conditions: [a] 5-X-indole (0.1 mmol), acrylic acid (1.5 equiv,
0.15 mmol), Pd catalyst (5 mol%), ligand (12.5 mol%), Na2CO3 (4 equiv,
0.4 mmol), CH3CN/H2O (1:1, 1 mL), conventional or microwave heating (T=
80 8C), solids and solvents purged with argon. [b] Based on ratio of starting
material aromatic peak at dH 6.40 ppm compared to product aromatic
peak at dH 6.50 ppm in CD3OD. [c] Isolated yields are reported after flash
chromatography.
Table 3. Heck cross-coupling of 5-X-indoles with different alkenes using
Na2PdCl4/
sSPhos as catalytic system.
Entry X R Product Conv. [%][a,b] Yield [%][c]
1 5-I 1 CO2Et 8 13 >99 60
[d]
2 5-I 1 COOH 2 3 >99 92
3 7-I 5 COOH 2 14 >99 91
4 5-I 1 COMe 9 15 >99 85
5 5-I 1 CN 10 16 >99 75
6 5-I 1 Ph 11 17 33 –
7 5-Br 4 CO2Et 12 13 >99 71
[d]
8 5-Br 4 COOH 2 3 >99 94
9 6-Br 6 COOH 2 18 >99 83
10 7-Br 7 COOH 2 14 >99 89
Reaction conditions: [a] 5-X-indole (0.1 mmol), alkene (1.5 equiv,
0.15 mmol) Na2PdCl4 (5 mol%),
sSPhos (15 mol%), Na2CO3 (4.0 equiv,
0.4 mmol), CH3CN/H2O (1:1, 1 mL), MW heating used, solids and solvents
purged with argon. [b] Based on ratio of starting material aromatic peak at
dH 6.40 ppm compared to product aromatic peak at dH 6.50 ppm in
CD3OD. [c] Isolated yields are reported after flash chromatography. [d] De-
sired product formed alongside acrylic acid derivative due to hydrolysis of
the ethyl ester under basic conditions. Yields are reported for the ethyl ac-
rylate product only.
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found suitable to afford almost quantitative conversion of
5-bromo and 6-bromo-tryptophan 19 and 22 (Table 4, entries 9
and 10). Importantly, as seen for the halo-indoles the reaction
is highly stereoselective towards the E product (See Supporting
Information).
Observed limitations in reactivity
The 4-bromo-tryptophan 23 is highly unreactive and even
using TXPTS as ligand, only a small trace of product may be
perceived from the reaction. Curiously, the sole application of
Heck cross-coupling to tryptophan reported in the literature is
the functionalisation of 4-bromo-tryptophan 23 in the synthe-
sis of clavicipitic acid (reported as 91% conversion using con-
ventional heating);[15] we have been unable to reproduce this
conversion using either the system that we have developed or
their conditions with alkene 1,1-dimethylallyl alcohol, TPPTS,
Pd(OAc)2 and NaOH as base. Forcing the reaction by MW heat-
ing to 130 8C for 2 h we were finally able to obtain a conver-
sion of around 15%.
The less reactive aryl chloride, as a component of either the
simple indole system or within tryptophan is also recalcitrant
to Heck modification under all conditions that we have ex-
plored. However, we demonstrate that following protection of
the primary amine (using N-Boc-4-bromo-tryptophan), Heck
coupling at position 4 can be achieved using our conditions. A
similar trend was observed for reactivity of free versus protect-
ed 2-bromo or 4-bromo-phenylalanine. These observations
strongly indicate influence of free a-amino group on the Pd-
catalysed cross-coupling of 4-halo-tryptophans (see Supporting
Information).
With conditions established that would enable the conver-
sion of 5, 6 and 7-iodo and bromo-tryptophans, we next set
out to explore the impact of sterics and electronic and solubili-
ty of the cross-coupling partners (Scheme 2). Through this we
could observe that progression from acrylic acid to bulkier aro-
matic substrates could be successfully achieved. Trend in cou-
pling efficiency seems to follow electronics rather than sub-
strate solubility. It is evident from the results that electron do-
nating substituents (i.e. Me or amino) decrease the reactivity of
alkene resulting in lower yields (51–65%, compounds 31–34).
On the contrary, electron-withdrawing fluoro or nitrile deriva-
tives gave significantly higher yields (80–92%, compounds
35–39), and reactions also worked well with heterocyclic
alkene substrates such as 4-vinylpyridine (compounds 40 and
41).
From NMR characterisation of the products, it may be seen
that for the 5-bromo and 5-iodo-tryptophan, an almost equal
mixture of the E and Z isomer are generated, whereas for the
7-bromo and 7-iodo-tryptophans the E stereoisomers predomi-
nate (see Supporting Information).
The selective diversification of natural products is an impor-
tant area. Such work can enable systematic modification and
optimisation of a bioactive molecule’s properties, or enable
tagging and tracking, or be utilised in target identity. As proof
of principle, we next set out to explore whether Heck cross-
coupling might be applied to the cross-coupling of tryptophan
residues within two test-bed natural products. The sponge
halo-metabolite barettin, a brominated a diketopiperazine-type
cyclic dipeptide (42, Scheme 3), is known for its roles in chemi-
cal defence against predators, antifouling activity and binding
to serotonergic 5-HT receptors.[21] Heck modulation could be
potentially explored to enable analogue generation to gain
greater understanding of the molecule’s structure–activity rela-
tionship. Furthermore, Heck tagging impacts upon the fluores-
cence of halo-indoles/tryptophans, such a strategy could po-
tentially be applied to enable the tissues in which it is generat-
Table 4. Heck cross-coupling on unprotected halo-tryptophans with acrylic
acid.
Entry X Prod Ligand t [h] T [8C] Conv. [%][a,b] Yield [%][c]
1 5-Br 19 25 SSPhos 1 80 <1 –
2 5-Br 19 25 SSPhos 2 100 <1 –
3 7-I 20 26 TPPTS 1 90 65 –
4 7-I 20 26 TPPTS 2 90 >99 93
5 7-I 20 26 TXPTS 1 80 24 –
6 7-I 20 26 TXPTS 1 90 >99 93
7 7-Br 21 26 TPPTS 2 90 47 –
8 7-Br 21 26 TXPTS 1 90 >99 87
9 5-Br 19 25 TPPTS 1 90 >99 95
10 6-Br 22 27 TPPTS 1 90 >99 –[d]
11 4-Br 23 28 TXPTS 1 90 <1 –
12 5-Cl 24 25 TXPTS 1 90 <1 –
Reaction conditions: [a] Halo-tryptophan (0.05 mmol, 1.0 equiv), acrylic acid
(0.075 mmol, 1.5 equiv), Na2PdCl4 (10 mol%), ligand (23 mol%), Na2CO3
(4 equiv), water/acetonitrile (3:1, 1 mL, degassed), microwave heating, 90 8C,
1 h. [b] Based on NMR ratios of starting material to product material in
CD3OD. [c] Products purified by reverse phase chromatography with a
MeOH/H2O gradient. [d] Product could not be isolated pure due to potential
degradation through reverse-phase column chromatography.
Scheme 2. Scope of alkene partner with styrene derivatives. The impact of
modification of sterics and electronics is explored.
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ed to be seen, as well as enabling tracking of the metabolite
and potentially revealing its targets.
Within barettin, the primary amine and carboxylate of tryp-
tophan, that would usually add challenge to cross-coupling re-
action progression, are masked as amides within a diketopiper-
azine. Many marine metabolites are highly lipophilic, limiting
their diffusion from their producer, enabling the producer to
retain the metabolites. To dissolve barettin, a higher ratio of
acetonitrile was required. Once dissolved, the reaction pro-
ceeded well, affording product 43.
Pacidamycin, belonging to the class of uridyl peptide antibi-
otics, represents a potentially more challenging substrate,
comprised of a pseudo-peptide backbone attached via an exo-
cyclic enamide to a modified uridine. We had previously dem-
onstrated the first out of context use of a halogenase, by intro-
ducing the gene encoding tryptophan-7-halogenase prnA in
Streptomyces coeruleorubidis (RG-5059) in order to generate
Cl-pacidamycin.[6a] We successfully utilized a synthetic biologi-
cal approach to generate an engineered strain (S. coelicolor
M1154, named RG1104) capable of generating new bromo-
metabolites, Br-pacidamycin D (44) and performing Suzuki–
Miyaura derivatisation to gain access to the analogue aryl-paci-
damycin D (Scheme 4).[8]
In this study, we employed the same strain in ISP2 medium
for production and isolation of Br-pacidamycin D and cultures
were grown for a total of 7–8 days. Production of Br-pacidamy-
cin D along with wild type pacidamycin D was detected by
LC-HRMS analysis. Isolation of the target compounds followed
sequence of purification steps: solid-phase extraction (XAD-16
resin), enrichment of pacidamycins using ion exchange chro-
matography (HiTrap SP-FF columns) and reverse phase purifi-
cation (semi-preparative HPLC) (see Supporting Information for
details).
In this manner, reasonably pure samples of wild-type pacida-
mycin D (1 mg) and Br-pacidamycin D (ca. 0.5 mg) were isolat-
ed. With the isolated material in hand, we could perform par-
tial NMR analysis on these samples. While the 1H NMR on paci-
damycin D was satisfactory, peak broadening was observed for
the brominated analogue. Gratifyingly, some key differences
were noted by careful comparison of the HSQC-NMR (see Sup-
porting Information), notably 1H and 13C peak at 7.35 and
110.7 ppm for pacidamycin D was absent in the HSQC spec-
trum of Br-pacidamycin D, thus indicating substitution in de-
sired position. LC-HRMS2 analyses showed desired isotope pat-
tern (m/z 790, 792 for 79Br, 81Br, respectively) and satisfactory
MS2 fragmentation was obtained (see Supporting Information).
To enable the modification of bromo-pacidamycin through
application of Heck chemistry we first explored reactions on
crude extracts containing very low concentrations of this
bromometabolite. Using our optimum conditions developed
for Br-tryptophan, we were pleased to see full conversion of
Br-pacidamycin D from crude extract and LC-HRMS2 analyses
confirmed formation of the desired cross-coupling product.
Next, we carried out the Heck coupling on a purified sample of
Br-pacidamycin D (ca. 0.5 mg). Although the cross-coupling
was successful as confirmed by LC-HRMS2 analysis (LC-HRMS2
product m/z C40H47FN9O10
+ [M+H]+ : 832.3424; found:
832.3422), the corresponding product 45 could not be success-
fully isolated on this very small scale. These results indicated
that our method has the potential to be utilised for micro-
scale tagging or functionalisation of brominated metabolites,
even as components of a complex extract without the need
for prior application of purification or protection strategies.
Conclusions
We have developed conditions enabling Heck cross-coupling
of iodo- and bromo-indoles and free unprotected 5, 6 and 7-
bromo-tryptophan and 7-iodo-tryptophan, showing the reac-
Scheme 3. Application of Heck to the diversification of the marine natural
product, barettin. Reaction carried out on a 2 mg scale.
Scheme 4. Application of Heck to the diversification of pacidamycin.
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tion to be very high yielding. Near quantitative cross-coupling
of iodo- and bromo-indoles can be achieved in the absence of
ligand, however to enable comparable conversions of halo-
tryptophans, a water-soluble ligand is required, and we found
that TXPTS and TPPTS could be used effectively. While high
conversions could be achieved for 5, 6, and 7-iodo and bromo-
indoles and tryptophans, exploration of limitation of scope re-
vealed the less reactive aryl chlorides to be recalcitrant to
cross-coupling under our conditions, 4-halo species also
proved demanding.
We have demonstrated the ability to carry out Heck modifi-
cation of halo-tryptophan with a wide range of alkenyl cross-
coupling partners. Introducing this chemistry to more sensitive
and complex systems in which halo-tryptophans are embed-
ded, we have used synthetic biology to engineer the produc-
tion of the halo-metabolite, bromo-pacidamycin, and have
demonstrated the selective modification of this polar antibiot-
ic, even as a component of a complex extract. We have also
demonstrated the application of these conditions to the modi-
fication of barettin, a natural and lipophilic metabolite ob-
tained from a sponge.
The fairly mild aqueous conditions, the high conversions
and flexibility of the substrate scope, make the Heck reaction a
useful tool for application to chemical biology and molecule
tagging as well as to GenoChemetic approaches to natural
product analogue generation. Tryptophan is an important resi-
due in natural products, peptides and proteins with a key role
in folding, function and fluorescence. The extension and mod-
ulation of the conjugation enabled by Heck cross-coupling
with series of alkene partners provides the potential for tuning
the conformation and modulating fluorescence properties.
Experimental Section
Proton (1H), and carbon NMR (13C) were recorded on either a
Bruker Ascend HD700 (700 MHz), Bruker Ascend 500 (500 MHz) or
a Bruker 400 UltraShield (400 MHz) spectrometer. The NMR experi-
ments were carried out in deuterated chloroform (CDCl3) deuterat-
ed water (D2O), deuterated DMSO ([D6]DMSO) or deuterated meth-
anol ([D4]MeOH). The chemical shifts (d) are quoted in parts per
million (ppm). Using a DEPTQ sequence or an HSQC experiment
with multiplicity editing, the 13C NMR signals were identified to
CH3, CH2, CH and C. Coupling constants are reported in Hertz (Hz).
High- and low-resolution mass spectra that were recorded at the
University of St. Andrews on an Orbitrap VELOS pro. Freeze drying
was carried out on a Scanvac CoolSafe freeze dryer. Microwave re-
actions were performed in sealed vials using a Biotage Initiator+
microwave reactor. UPLC analysis was acquired on a Waters Acqui-
ty H-Class UPLC system fitted with a Waters Acquity UPLC BEH C18
column (1.7 mm, 2.150 mm) or Phenomenex Kinetex Phenyl-hexyl
column (2.1 mm, 2.175 mm).
Flash chromatography was performed using Davisil silica gel
LC60A (40–63 micron). Thin layer chromatography (TLC) was exe-
cuted using aluminium sheets of silica gel 60 F254 and was visual-
ised under a Mineralight model UVGL-58 lamp (254 nm). The plates
were developed with ninhydrin in acetone or basic potassium per-
manganate solutions. Purification of unprotected tryptophan deriv-
atives and peptides was carried out on a Biotage Isolera Four
using reverse-phase SNAP C18 12 g column cartridges. The purifi-
cation was carried out using water (solvent A) and methanol/aceto-
nitrile (solvent B) using the following gradient: 0–1.5 min (5% B),
1.5–3.0 min (5% to 15% B), 3.0–5.0 min (15% B), 5.0–15.0 min
(15% to 95% B), 15.0–18.0 min (95% B), 18.0–20.0 min (95%-5%
B), 20.0–25.0 min (5% B) at a flow rate of 12–15 mLmin1.
Preparative RP-HPLC purification was performed using a Gilson 322
pump, 151 UV/Vis detector and 233XL fraction collector, using a
Phenomenex Luna C18 (5 micron, 25021.2 mm) with UV detec-
tion at 234 nm. Elution was carried out using a shallow linear gra-
dient with starting conditions 95% solvent A (0.1% formic acid in
MQ water) to 5% solvent B (ACN) to 40% solvent B over 40 min.
Experimental details and characterisation data N-Boc protection of
4-Br-(S)-tryptophan, it’s subsequent Heck coupling and deprotec-
tion affording compound 28, as well as Heck reaction for N-Boc-4-
Br-phenylalanine and N-Boc-2-Br-phenylalanine are presented in
the Supporting Information.
General protocol for Heck cross-coupling of halo-indoles with al-
kenes in aqueous conditions : In a 10 mL pear-shape flask or 0.5-
2 mL MW vial, sodium tetrachloropalladate (1.6 mg, 5 mmol,
5 mol%), sulfonated SPhos (6.6 mg, 12.5 mmol, 12.5 mol%) were
purged with nitrogen and stirred at RT for 15 min after adding
1 mL of degassed water/acetonitrile (1:1) mixture. Then, appropri-
ate halo-indole (0.1 mmol, 1.0 equiv) is added together with
Na2CO3 (22 mg, 0.2 mmol, 2 equiv) followed by addition of the
alkene (0.15 mmol, 1.5 equiv). The reaction mixture was heated at
80 8C (MW or conventional heating) for the required period of
time. The reaction mixture was cooled to RT and diluted with 5 mL
of a saturated solution of NaHCO3. The aqueous layer was extract-
ed with ethyl acetate (310 mL). The combined organic layers
were dried over anhydrous Na2SO4 and the solvent removed in
vacuo. Purification by column chromatography using silica gel
(Hexanes/ethyl acetate 4:1). Characterisation data for isolated
indole-Heck products (3, 13–18) are presented in the Supporting
Information.
General protocol for Heck cross-coupling of unprotected halo-
tryptophans with acrylic acid in aqueous conditions : In a 0.5-
2 mL MW vial, sodium tetrachloropalladate (1.5 mg, 5 mmol,
10 mol%), with appropriate ligand (TPPTS 6.5 mg or TXPTS:
7.0 mg, 11.5 mmol, 23 mol%) were purged with argon and stirred
at RT for 15 min after adding 1 mL of degassed water/acetonitrile
(3:1) mixture, 1 mL. Then, the corresponding halo-tryptophan
(0.05 mmol) was added together with Na2CO3 (22 mg, 0.2 mmol,
4 equiv) followed by addition of the acrylic acid (6 ml, 0.075 mmol,
1.5 equiv). The vial was closed, and the reaction mixture was stirred
and heated at 90 8C (MW) for 1 hour. After completion, the reaction
was cooled down to room temperature was diluted with water
(2 mL) and acidified (pH=2–3) using 0.1m HCl. Solvent was re-
moved under reduced pressure. The desired product was obtained
by purification using gradient reversed phase chromatography
(C18, 12 g) eluting with MeOH–water (5–95% gradient).
(E)-3-(3-((S)-2-amino-2-carboxyethyl)-1H-indol-5-yl)acrylic acid
(25): Using TPPTS as a ligand, the above procedure afforded 13 mg
(95% from 5-Br-tryptophan) of the title product as a white solid.
1H NMR (400 MHz, MeOD): d=8.01 (s, 1H, ArH), 7.84 (d, J=
15.9 Hz, 1H, CH=CH-Ar), 7.51–7.33 (m, 2H, ArH), 7.25 (s, 1H, ArH),
6.46 (d, J=15.9 Hz, 1H, CH=CH-Ar), 3.89 (dd, J=9.1, 4.1 Hz, 1H,
CH), 3.52 (dd, J=15.0, 4.5 Hz, 1H, CHAHB), 3.19 ppm (dd, J=15.3,
9.1 Hz, 1H, CHAHB).
13C NMR (126 MHz, [D6]DMSO) d=170.1 (CO),
168.3 (CO-CH=CH), 146.1 (CO-CH=CH-Ar), 137.6 (C), 127.7 (C), 125.6
(CH), 124.9 (C), 121.1 (CH), 120.3 (CH), 115.3 (CO-CH=CH-Ar), 111.8
(CH), 110.6 (C), 54.7 (CH), 26.9 ppm (CH2). HRMS (FTMS -p NSI)
C14H13N2O4 [MH] calculated for 273.0881, found 273.0880.
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(E)-3-(3-((S)-2-amino-2-carboxyethyl)-1H-indol-7-yl)acrylic acid
(26): The above procedure afforded 11.9 mg (87% from 7-Br-tryp-
tophan) and 12.7 mg (93% from 7-I-tryptophan) of the desired
product as a white solid.
1H NMR (400 MHz, MeOD) d=8.10 (d, J=16.0 Hz, 1H, CH=CH-Ar),
7.80 (d, J=7.5 Hz, 1H, ArH), 7.47 (d, J=7.4 Hz, 1H, ArH), 7.29 (s,
1H, ArH), 7.13 (t, J=7.7 Hz, 1H, ArH), 6.57 (d, J=16.0 Hz, 1H, CH=
CH-Ar), 3.87 (dd, J=9.1, 4.1 Hz, 1H, CH), 3.52 (dd, J=15.3, 4.0 Hz,
1H, CHAHB), 3.20 ppm (dd, J=15.3, 9.1 Hz, 1H, CHAHB).
13C NMR
(101 MHz, MeOD) d=174.2 (CO), 171.0 (CO-CH=CH), 142.2 (CO-
CH=CH-Ar), 136.7 (C), 129.8 (C), 126.2 (CH), 122.5 (CH), 122.1 (CH),
120.6 (CH), 119.9 (C), 119.3(CO-CH=CH-Ar), 110.6 (C), 56.6 (CH),
28.2 ppm (CH2). HRMS (FTMS -p NSI) C14H13N2O4 [MH] calculated
for 273.0881, found 273.0884.
(E)-3-(3-((S)-2-amino-2-carboxyethyl)-1H-indol-6-yl)acrylic acid
(27): Using TPPTS as a ligand, after completion, the reaction was
cooled down to RT was diluted with water (2 mL) and acidified
(pH=2–3) using 0.1m HCl. Solvent was removed under reduced
pressure. 1NMR analysis showed clearly full conversion (>99%) to-
wards the title product. Unfortunately, our attempts to purify the
product by reverse phase chromatography failed as the product
seems to degrade through C18 even at neutral pH (7). 1H NMR ex-
tracted from the mixture of final product and partially oxidized
TXPTS.
1H NMR (500 MHz, MeOD) d=7.78–7.75 (m, 2H, overlapping ArH,
CH=C), 7.60 (s, 1H, ArH), 7.38 (dd, J=8.4, 1.4 Hz, 1H, ArH), 7.33 (s,
1H, ArH), 6.46 (d, J=15.9 Hz, 1H, C=CH), 3.87 (dd, J=9.1, 4.2 Hz,
1H, CH), 3.52 (dd, J=15.2, 4.1 Hz,1H, CHAHB), 3.20 ppm (dd, J=
15.2, 9.1 Hz, 1H, CHAHB).
13C NMR (126 MHz, MeOD) d=172.6 (CO),
169.8 (CO)*, 146.5 (CH), 137.0 (C), 129.0 (C), 128.2 (C), 126.3 (CH),
118.4 (CH), 118.5 (CH), 115.5 (CH), 112.2 (CH), 108.7 (C), 55.3 (CH),
26.8 ppm (CH2).* Identified from HMBC spectrum. HRMS (FTMS -p
NSI) C14H13N2O4 [MH] calculated for 273.0881, found 273.0871.
General protocol for Heck cross-coupling of unprotected halo-
tryptophans with styrene derivatives in aqueous conditions. In a
0.5-2 mL MW vial, sodium tetrachloropalladate (1.5 mg, 10 mmol,
10 mol%), TXPTS (7.0 mg, 23 mmol, 23 mol%) were purged with
argon and stirred at RT for 15 min after adding 1 mL of degassed
water/acetonitrile (3:1) mixture. Then, appropriate halo-tryptophan
(0.05 mmol) was added together with Na2CO3 (22 mg, 0.2 mmol,
4 equiv) followed by addition of the styrene derivative coupling
partner (0.075 mmol, 1.5 equiv). The vial was closed and the reac-
tion mixture was stirred and heated at 90 8C (MW) for 2 hours.
After completion, the reaction cooled down to RT was diluted with
water (2 mL) and extracted with diethyl ether (32 mL) to remove
the excess of the alkene coupling partner. The aqueous layer was
acidified (pH=2–3) using 0.1m HCl. Solvent was removed under
reduced pressure. The desired product was obtained by purifica-
tion using gradient reversed phase chromatography (C-18, 12 g)
eluting with water-MeOH (5–95% gradient).
(S)-2-amino-3-(5-styryl-1H-indol-3-yl)propanoic acid (29): The
above procedure afforded 10.9 mg (72% from 5-Br-tryptophan) of
the desired product as a white solid. LC-MS analysis indicated the
presence of separable E and Z isomers (4:1).
1H NMR (500 MHz, MeOD) d=7.89 (s, 1H, CH), 7.58–7.50 (m, 2H,
CH=CH), 7.43 (dd, J=8.5, 1.4 Hz, 1H, ArH), 7.39–7.27 (m, 4H, ArH),
7.23–7.11 (m, 3H, ArH), 3.95 (dd, J=9.4, 4.3 Hz, 1H, CH), 3.55 (dd,
J=15.6, 4.3 Hz, 1H, CHAHB), 3.20 ppm (dd, J=15.6, 9.4 Hz, 1H,
CHAHB).
13C NMR (126 MHz, MeOD) d=174.4 (CO), 139.6 (C), 138.3
(C), 131.3 (CH), 130.3 (C), 129.8 (2CH), 128.8 (C), 127.8 (CH), 127.1
(2CH), 126.6 (CH), 125.9 (CH), 121.6 (CH), 118.2 (CH), 112.7 (CH),
110.1 (C), 56.7 (CH), 28.5 ppm (CH2). HRMS (FTMS -p NSI)
C19H19N2O2 [MH] calculated for 307.1441, found 307.1437.
(S)-2-amino-3-(7-(E)-styryl-1H-indol-3-yl)propanoic acid (30): The
above procedure afforded 9.8 mg (65% from 7-Br-tryptophan) of
the desired product as a white solid.
1H NMR (500 MHz, MeOD) d=7.69–7.66 (m overlapped, 3H), 7.65
(overlapped, 1H), 7.49 (d, J=7.4 Hz, 1H), 7.39 (t, J=7.7 Hz, 2H),
7.30 (overlapped, 1H), 7.29 (overlapped, 1H), 7.27 (overlapped,
1H), 7.12 (t, J=7.4 Hz, 1H), 3.90 (dd, J=9.3, 4.1 Hz, 1H, CH), 3.55
(dd, J=15.2, 4.1 Hz, 1H, CHAHB), 3.20 ppm (dd, J=15.2, 9.3 Hz, 1H,
CHAHB).
13C NMR (126 MHz, MeOD) d=173.0 (CO), 137.9 (C), 135.0
(C), 128.5 (C), 128.3 (2CH), 127.9 (C), 127.0 (CH), 126.1 (2CH), 124.1
(CH), 123.9 (CH), 121.5 (C), 119.3 (CH), 118.3 (CH), 117.6 (CH), 108.7
(C), 55.3 (CH), 27.0 ppm (CH2). HRMS (FTMS -p NSI) C19H17N2O2
[MH] calculated for 305.1296, found 305.1292.
(S)-2-amino-3-(5-(4-methylstyryl)-1H-indol-3-yl)propanoic acid
(31): The above procedure afforded 9.9 mg (62% from 5-Br-trypto-
phan) of the desired product as a yellowish solid. LC-MS analysis
indicated the presence of separable E and Z isomers (7:1).
1H NMR (500 MHz, MeOD) d=7.91 (s, 1H), 7.45 (d, J=8.2 Hz, 2H),
7.43 (dd, J=8.6, 1.4 Hz, 1H), 7.37 (d, J=8.6 Hz, 1H), 7.26 (d, J=
16.3 Hz, 1H), 7.21 (s, 1H), 7.17 (d, J=8.2 Hz, 2H), 7.12 (d, J=
16.3 Hz, 1H), 3.91 (dd, J=9.7, 3.8 Hz, 1H), 3.57 (dd, J=15.2, 3.8 Hz,
1H), 3.18 (dd, J=15.2, 9.7 Hz, 1H), 2.35 ppm (s, 3H). 13C NMR
(126 MHz, MeOD) d=173.1 (CO), 136.8 (C), 136.3 (C), 135.4 (C),
129.1 (C), 128.9 (CH), 128.9 (2CH), 127.4 (C), 125.7 (2CH), 125.2 (CH),
124.4 (CH), 120.2 (CH), 116.6 (CH), 111.3 (CH), 108.7 (C), 55.3 (CH),
27.2 (CH2), 19.9 ppm (CH3). HRMS (FTMS +p ESI) m/z C20H21N2O2
+
[M+H]+ calculated 321.1598, found 321.1595.
(S)-2-amino-3-(5-(4-aminostyryl)-1H-indol-3-yl)propanoic acid
(33): The above procedure afforded 10.4 mg (65% from 5-Br-tryp-
tophan) of the desired product as a yellowish solid. LC-MS analysis
indicated the presence of separable E and Z isomers (2:1).
1H NMR (500 MHz, MeOD) d=7.61 (s, 1H, ArH), 7.34 (d, J=8.5 Hz,
1H, ArH), 7.21–7.18 (m, 2H, ArH, CH=), 7.04 (d, J=8.4 Hz, 2H,
ArH), 6.74 (d, J=8.4 Hz, 1H, ArH), 6.58 (d, J=12.1 Hz, 1H,=CH),
6.55 (d, J=8.4 Hz, 2H, ArH), 3.78 (dd, J=9.6, 4.1 Hz, 1H, CH), 3.46
(dd, J=15.1, 4.1 Hz, 1H, CHAHB), 3.07 ppm (dd, J=15.1, 9.6 Hz, 1H,
CHAHB).
13C NMR (126 MHz, MeOD) d=172.9 (CO), 146.6 (C-NH2),
136.1 (C), 129.6 (CH), 129.0 (C), 128.0 (CH), 127.4 (C), 127.0 (C),
126.7 (CH), 125.7 (CH), 124.1 (CH), 122.7 (CH), 118.5 (CH), 115.3
(CH), 114.7 (CH), 110.6 (CH), 108.5 (C), 55.3 (CH), 27.0 ppm (CH2).
HRMS (FTMS +p ESI) m/z C19H20N3O2 [M+H]
+ calculated 322.1550,
found 322.1544.
(S)-2-amino-3-(7-(4-aminostyryl)-1H-indol-3-yl)propanoic acid
(34): The above procedure afforded 8.8 mg (55% from 7-Br-trypto-
phan) of the desired product as a yellowish solid. LC-MS analysis
indicated the presence of separable E and Z isomers (8:1).
1H NMR (500 MHz, MeOD) d=7.60 (t, J=7.7 Hz, 1H, ArH), 7.40
(dd, J=8.4, 2.9 Hz, 2H, ArH), 7.33- 7.28 (m, 1H, CH=), 7.18–7.01
(m, 2H, ArH), 7.01–6.90 (m, 1H, CH=), 6.73 (d, J=8.4 Hz, 1H, ArH),
6.59 (s, 1H, ArH), 6.46 (d, J=8.5 Hz, 1H, ArH), 3.87 (dt, J=9.3,
3.4 Hz, 1H, CH), 3.52 (dt, J=14.9, 4.0 Hz, 1H, CHAHB), 3.15 ppm (dt,
J=15.4, 9.1 Hz, 1H, CHAHB).
13C NMR (126 MHz, MeOD) d=174.4
(CO), 148.7 (C-NH2), 148.5 (C), 136.2 (C), 132.5 (CH), 131.0 (CH),
129.3 (C), 128.8 (C), 128.6 (CH), 125.3 (CH), 123.7 (C), 122.7 (CH),
120.7 (CH), 120.1 (CH), 119.0 (CH), 118.1 (CH), 116.5 (CH), 109.9 (C),
56.7 (CH), 28.5 ppm (CH2). HRMS (FTMS +p ESI) m/z C19H20N3O2
[M+H]+ calculated 322.1550, found 322.1544.
(S)-2-amino-3-(5-(4-fluorostyryl)-1H-indol-3-yl)propanoic acid
(35): The above procedure afforded 14.6 mg (90% from 5-Br-tryp-
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tophan) of the desired product as a yellowish solid. LC-MS analysis
indicated the presence of separable E and Z isomers (15:1).
1H NMR (500 MHz, MeOD) d=7.88 (s, 1H), 7.56 (dd, J=8.7, 5.4 Hz,
2H), 7.43 (dd, J=8.5, 1.2 Hz, 1H), 7.36 (d, J=8.5 Hz, 1H), 7.28–7.13
(m, 3H), 7.07 (t, J=8.8 Hz, 2H), 3.96 (dd, J=9.2, 4.0 Hz, 1H, CH),
3.55 (dd, J=15.1, 4.0 Hz, 1H, CHAHB), 3.20 ppm (dd, J=15.1, 9.2 Hz,
1H, CHAHB).
13C NMR (126 MHz, [D6]DMSO) d=170.5 (CO), 161.2
(d, JC-F=248 Hz, CF), 136.3 (C), 134.4 (C), 130.3 (CH), 127.7 (d, JC-F=
6.2 Hz, CH),), 125.2 (CH), 123.7 (CH), 119.8 (CH), 117.5 (CH), 115.5 (d,
JC-F=21.2 Hz, CH), 111.8 (CH), 109.4 (C), 54.2 (CH), 26.9 ppm (CH2).
19F NMR (471 MHz, MeOD) d=115.4 (major), 114.8 ppm
(minor) isomer. HRMS (FTMS +p ESI) m/z C19H18FN2O2 [M+H]
+ cal-
culated 325.1347, found 325.1337.
(S)-2-amino-3-(7-((E)-4-fluorostyryl)-1H-indol-3-yl)propanoic acid
(36): The above procedure afforded 12.9 mg (80% from 7-Br-tryp-
tophan) of the desired product as a yellowish solid.
1H NMR (500 MHz, MeOD) d=7.68–7.65 (m overlapped, 3H), 7.58
(d, J=16.3 Hz, 1H), 7.47 (d, J=7.4 Hz, 1H), 7.29 (s, 1H), 7.27 (d, J=
16.3 Hz, 1H), 7.14–7.10 (m, overlapped, 3H), 3.89 (dd, J=9.3,
4.1 Hz, 1H, CH), 3.55 (dd, J=15.3, 4.1 Hz, 1H, CHAHB), 3.20 ppm
(dd, J=15.3, 9.3 Hz, 1H, CHAHB).
13C NMR (126 MHz, MeOD) d=
173.0 (CO), 162.2 (d, JC-F=245.8 Hz, CF), 135.0 (C), 134.3 (C), 127.9
(C), 127.8 (d, JC-F=7.9 Hz, CH), 127.2 (CH), 124.1 (CH), 123.9 (CH),
121.4 (C), 119.3 (CH), 118.3 (CH), 117.7 (CH), 115.1 (d, JC-F=21.9 Hz,
CH), 108.7 (C), 55.4 (CH), 27.0 ppm (CH2).
19F NMR (471 MHz,
MeOD) d=117 ppm. HRMS (FTMS +p ESI) m/z C19H18FN2O2
[M+H]+ calculated 325.1347, found 325.1342.
(S)-2-amino-3-(7-((E)-3-fluorostyryl)-1H-indol-3-yl)propanoic acid
(37): The above procedure afforded 14.9 mg (92% from 7-Br-tryp-
tophan) of the desired product as a white solid.
1H NMR (500 MHz, MeOD) d=7.73–7.62 (m, 2H), 7.49 (d, J=
7.4 Hz, 1H), 7.45–7.33 (m, 3H), 7.26 (d, J=17.0 Hz, 2H), 7.11 (t, J=
7.6 Hz, 1H), 6.98 (td, J=8.3, 1.9 Hz, 1H), 3.91 (dd, J=9.1, 4.1 Hz,
1H, CH), 3.53 (dd, J=15.2, 4.1 Hz, 1H, CHAHB), 3.20 ppm (dd, J=
15.2, 9.1 Hz, 1H, CHAHB).
13C NMR (126 MHz, MeOD) d=174.2 (CO),
164.7 (d, JC-F=242 Hz, CF), 141.9 (d, JC-F=8.8 Hz, C), 136.5 (C), 131.3
(d, JC-F=8.8 Hz, CH), 129.4 (C), 128.3 (CH), 126.9 (CH), 125.6 (CH),
123.7 (CH), 122.4 (C), 120.7 (CH), 119.9 (CH), 119.4 (CH), 114.9 (d, JC-
F=22 Hz, H-C-CF), 113.4 (d, JC-F=28 Hz, H-C-CF), 110.00 (C), 56.5
(CH), 28.3 ppm (CH2).
19F NMR (377 MHz, [D6]DMSO) d=
113.5 ppm. HRMS (FTMS +p ESI) m/z C19H18FN2O2 [M+H]+ calcu-
lated 325.1347, found 325.1338.
(S)-2-amino-3-(5-((E)-4-cyanostyryl)-1H-indol-3-yl)propanoic acid
(38): The above procedure afforded 15 mg (91% from 5-Br-trypto-
phan) of the desired product as a yellowish solid.
1H NMR (500 MHz, MeOD) d=7.96 (s, 1H, ArH), 7.77–7.61 (m, 4H,
ArH, CH=), 7.60–7.44 (m, 2H, ArH), 7.39 (d, J=8.5 Hz, 1H, ArH),
7.26–7.13 (m, 2H, ArH), 3.93 (dd, J=9.1, 4.1 Hz, 1H, CH), 3.54 (dd,
J=15.1, 3.9 Hz, 1H, CHAHB), 3.21 ppm (dd, J=15.2, 9.1 Hz, 1H,
CHAHB).
13C NMR (126 MHz, DMSO) d=169.8 (CO), 142.8 (C), 136.7
(C), 134.4 (CH), 132.6 (CH), 127.6 (C), 127.1 (C), 126.6 (CH), 125.1
(CH), 123.1 (CH), 120.1 (CH), 119.3 (C), 118.5 (CH), 111.8 (CH), 110.4
(C), 108.5 (C), 54.7 (CH), 27.1 ppm (CH2). HRMS (FTMS -p NSI)
C20H16N3O2 [MH] calculated for 330.1248, found 330.1245.
(S)-2-amino-3-(7-((E)-4-cyanostyryl)-1H-indol-3-yl)propanoic acid
(39): The above procedure afforded 14.7 mg (89% from 7-Br-tryp-
tophan) of the desired product as a yellowish solid.
1H NMR (500 MHz, MeOD) d=7.86–7.75 (m, 3H, ArH), 7.74–7.65
(m, 3H, ArH, CH=), 7.51 (d, J=7.4 Hz, 1H, ArH), 7.31 (d, J=16.1 Hz,
1H, CH=), 7.29 (s, 1H, ArH), 7.13 (t, J=7.7 Hz, 1H, ArH), 3.98 (dd,
J=8.8, 4.4 Hz, 1H, CH), 3.52 (dd, J=15.3, 4.1 Hz, 1H, CHAHB),
3.23 ppm (dd, J=15.3, 8.8 Hz, 1H, CHAHB).
13C NMR (126 MHz,
MeOD) d=173.6 (CO), 144.2 (C), 136.5 (C), 133.6 (CH), 132.9 (CH),
130.7 (CH), 129.4 (CH), 128.1 (CH), 127.8 (CH), 125.9 (CH), 122.1 (C),
120.8 (CH), 120.4 (CN), 112.0 (CH), 111.2 (C), 109.8 (C), 55.7 ppm
(CH), 28.0 (CH2). HRMS (FTMS -p NSI) C20H16N3O2 [MH] calculat-
ed for 330.1248, found 330.1245.
(S)-2-amino-3-(5-(2-(pyridin-4-yl)vinyl)-1H-indol-3-yl)propanoic
acid (40): The above procedure afforded 13 mg (85% from 5-Br-
tryptophan) of the desired product as a reddish solid. LC-MS analy-
sis indicated the presence of separable E and Z isomers (3:1).
1H NMR (500 MHz, MeOD) d=8.51 (d, J=5.9 Hz, 2H, ArH), 7.86 (s,
1H, ArH), 7.66 (d, J=16.4 Hz, 1H, CH=CH-Py), 7.56 (d, J=5.5 Hz,
2H, ArH), 7.47 (d, J=8.5 Hz, 1H, ArH), 7.38 (d, J=8.4 Hz, 1H, ArH),
7.23 (s, 1H, ArH), 7.13 (d, J=16.4 Hz, 1H, CH=CH-Py), 3.91 (dd, J=
9.2, 3.6 Hz, 1H, CH), 3.56 (dd, J=15.0, 3.6 Hz, 1H, CHAHB), 3.21 ppm
(dd, J=15.0, 9.2 Hz, 1H, CHAHB).
13C NMR (126 MHz, MeOD) d=
173.0 (CO), 146.9 (CH-N), 131.1 (C), 129.6 (CH), 127.9 (C), 127.2 (CH),
126.8 (C), 123.8 (CH), 122.1(C), 121.3 (CH), 119.3 (CH), 118.7 (CH),
116.9 (CH), 108.5 (C), 55.3 (CH), 27.2 ppm (CH2). HRMS (FTMS +p
ESI) m/z C18H18N3O2 [M+H]
+ calculated 308.1394, found 308.1388.
(S)-2-amino-3-(7-((E)-2-(pyridin-4-yl)vinyl)-1H-indol-3-yl)propano-
ic acid (41): The above procedure afforded 10.9 mg (71% from 7-
Br-tryptophan) of the desired product as a reddish solid.
1H NMR (500 MHz, MeOD) d=8.47 (d, J=5.8 Hz, 2H, ArH), 7.95 (d,
J=16.4 Hz, 1H, CH=CH-Py), 7.74 (d, J=7.6 Hz, 1H, ArH), 7.64 (d,
J=6.1 Hz, 2H, ArH), 7.54 (d, J=7.4 Hz, 1H, ArH), 7.30 (s, 1H, ArH),
7.26 (d, J=16.3 Hz, 1H, CH=CH-Py), 7.14 (t, J=7.7 Hz, 1H, ArH),
3.88 (dd, J=9.1, 4.2 Hz, 1H, CH), 3.52 (dd, J=15.3, 4.2 Hz, 1H,
CHAHB), 3.20 ppm (dd, J=15.3, 9.1 Hz, 1H, CHAHB).
13C NMR
(126 MHz, MeOD) d=174.3 (CO), 150.2 (2CH-N), 148.1 (C), 136.6
(C), 131.3 (CH=CH-Py), 129.6 (C), 126.3 (CH=CH-Py), 125.8 (CH),
122.4 (2CH), 121.6 (C), 120.8 (CH), 120.7 (CH), 120.6 (CH), 110.3 (C),
56.6 (CH), 28.3 ppm (CH2). HRMS (FTMS +p ESI) m/z C18H18N3O2
[M+H]+ calculated 308.1394, found 308.1392.
Barettin purification from extract[21]
Barettin extract was kindly provided by Dr. Paco Crdenas, Uppsala
University, Sweden; 2 g of freeze-dried extract was added onto a
filter paper in a funnel and rinsed copiously with dichloromethane
to remove any lipids from the sample. After rinsing with DCM, the
freeze-dried extract was washed thoroughly with 60% aqueous
acetonitrile. The washings were checked via LCMS and combined.
The sample was concentrated to 1.5 mL.
Barretin extract was purified via RP-HPLC using a Phenomenex
Luna C18 (5 micron, 25021.2 mm) with UV detection at 234 nm.
The compound was eluted using a shallow linear gradient with
starting conditions 95% solvent A (0.1% formic acid in MQ water)
to 5% solvent B (ACN) to 40% solvent B over 40 min. Over the
next 15 min solvent B was increased to 95%, held isocratically for
5 min before returning to starting conditions. Barettin (8 mg)
eluted with a retention time of 37 min and was confirmed by
LCMS and characterised by NMR.
(R)-1-(3-(5-(((Z)-6-bromo-1H-indol-3-yl)methylene)-3,6-dioxopi-
perazin-2-yl)propyl)guanidine (42): 1H NMR (700 MHz, MeOD)
d=7.75 (s, 1H, Ar-CH), 7.66–7.46 (m, 2H), 7.24 (dd, 1H, J=8.5,
1.7 Hz, Ar-CH), 7.17 (s, 1H, Ar-CH), 4.20 (t, 1H, J=5.6 Hz, CH), 3.23–
3.19 (m, 2H, CH2), 1.99–1.93 (m, 1H, CHAHB) 1.92–1. 85 (m, 1H,
CHAHB), 1.77–1.66 ppm (m, 2H, CH2).
13C NMR (176 MHz, MeOD)
d=167.2 (CO), 162.1 (CO), 157.2 (C(NH)2NH2), 137.0 (C), 126.2 (CH),
126.1 (C), 123.2 (CH), 121.9 (CH), 119.5 (CH), 115.7 (C), 114.3 (CBr),
109.7 (CH), 108.5 (C), 55.1 (CH), 40.5 (CH2), 31.2 (CH2), 23.7 ppm
(CH2). MS (ESI) m/z 421 (100) [M(
81Br)+H]+ , 419 (100) [M(79Br)+
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H]+ ; HRMS (FTMS +p ESI): m/z calculated for: C17H20BrN6O
[M(79Br)+H]+ : 419.0826; found: 419.0809.
Heck cross-coupling on purified Barettin in aqueous conditions
giving 1-(3-((R)-5-(Z)-((6-(4-fluorostyryl)-1H-indol-3-yl)methy-
lene)-3,6-dioxopiperazin-2-yl)propyl)guanidine (43): A stock solu-
tion of catalyst was prepared as follows: sodium tetrachloropalla-
date (1.5 mg, 5 mmol), TXPTS (7.0 mg, 11.5 mmol, 23 mol%) were
purged with argon and stirred at RT for 15 min after adding 1 mL
of degassed water/acetonitrile (1:1) mixture. Then, in a separate
MW vial barretin (2 mg, 0.005 mmol) was added together with
Na2CO3 (2 mg, 0.02 mmol, 4 equiv) followed by addition of the 4-
fluorostyrene (4 mL, 0.15 mmol, 10 equiv) and Pd-catalyst (10 mol%
from stock). The vial was closed, and the reaction mixture was
stirred and heated at 90 8C (MW) for 2.5 hours. LC-MS analysis
showed full conversion. Purification was done via RP-HPLC using a
Phenomenex Luna C18 (5 micron, 25021.20 mm) with UV detec-
tion at 330 nm. The compound was eluted using a shallow linear
gradient with starting conditions 95% solvent A (0.1% formic acid
in MQ water) to 5% solvent B (ACN) to 40% solvent B over 40 min.
Over the next 15 min solvent B was increased to 95%, held isocrat-
ically for 5 min before returning to starting conditions. Barettin-
Heck derivative eluted with a retention time of 39 min and was
confirmed by LCMS and 1H NMR. Depicted product was obtained
0.5 mg (21% isolated yield) as a white solid.
1H NMR (700 MHz, MeOD) d=7.81 (s, 1H, Ar-CH), 7.69 (d, 1H, J=
8.4 Hz, Ar-CH) 7.65–7.54 (m, 3H), 7.47 (d, 1H, J=8.4 Hz, Ar-CH) 7.27
(s, 1H, Ar-CH), 7.19 (d, 1H, J=16.3 Hz, Ar-CH), 7.11 (t, 2H, J=
8.7 Hz, 2H) 4.25 (t, 1H, J=5.6 Hz, CH), 3.27–3.22 (m, 2H, CH2),
2.03–1.98 (m, 1H, CHAHB) 1.96–1. 89 (m, 1H, CHAHB), 1.82–1.70 ppm
(m, 2H, CH2).
19F NMR (659 MHz, MeOD) d=77.1 ppm. MS (ESI)
m/z 461.2 (100); HRMS (FTMS +p ESI): m/z calculated for
C25H26FN6O2 [M+H]
+ :461.2096; found: 461.2075.
Culture conditions and isolation of pacidamycin D and Br-
pacidamycin D (44).[8]
Starter cultures of engineered strain Streptomyces coelicolor
RG1104, with prnA knock-in (performed as previously reported)[3]
were obtained by inoculating 150 mL ISP2 medium with 0.3 mL
spore suspension (approximately 106–107 cfumL1 final concentra-
tion) and culturing for 24–48 hours at 28 8C, 220 rpm. Starter cul-
ture (20 mL) was then added to 0.5 L ISP2 and incubated with
shaking at 28 8C for 7–8 days. Pacidamycins were extracted from
the cell-free broth using 0.05 volumes of XAD-16 resin. The resin
was washed with 20 volumes of water and the extract was eluted
with 10 volumes of methanol. The solvent was removed in vacuo.
The crude extract was then purified by ion-exchange chromatogra-
phy using a 5 mL HiTrap SP-FF column (GE Healthcare). After load-
ing, the column was washed with 6 volumes 50 mm sodium ace-
tate, pH 3.6. Pacidamycins were eluted with 50 mm sodium acetate
in a stepwise gradient from pH 3.6 to pH 5.6. the appropriate paci-
damycin-containing fractions were combined and further purified
on a Luna C18(2) 25022.10 mm column, initial composition 10%
acetonitrile 90% RP buffer A, held for 2 min before reaching 40%
acetonitrile over 40 min compound eluted at around 28 min. Over
the next 20 min quick gradient up to 95% acetonitrile which was
held for 5 min before returning to starting conditions.
Pacidamycin-D : 1H NMR (700 MHz, MeOD) d=7.61 (d, J=7.7 Hz,
1H), 7.45 (d, J=8.2 Hz, 1H), 7.31 (dd, J=8.1, 1.8 Hz, 1H), 7.20 (s,
2H), 7.12–7.09 (m, 1H), 5.98 (s, 1H), 5.88 (s, 1H), 5.76 (dd, J=8.1,
1.9 Hz, 1H), 4.52 (ddq, J=8.6, 6.5, 2.1 Hz, 3H), 4.45 (dd, J=9.3,
2.0 Hz, 1H), 4.25 (qd, J=7.0, 1.9 Hz, 1H), 3.28–3.16 (m, 2H), 2.79 (d,
J=1.9 Hz, 3H), 2.59 (d, J=17.8 Hz, 1H), 1.41 (dd, J=7.1, 1.9 Hz,
1H), 1.29 (dd, J=7.0, 1.9 Hz, 3H), 1.22 (d, J=7.2 Hz, 3H), 1.12 ppm
(dd, J=6.9, 1.9 Hz, 3H).
MS (ESI) m/z 712 (100) HRMS (FTMS +p ESI): m/z calculated for
C32H42N9O10 [M+H]
+ 712.3049; found: 712.3044.
Br-Pacidamycin-D (44): Tabulated HSQC NMR data and comparison
with wild type pacidamycin D is given in SI. MS (ESI): 790 (100)
[M(79Br)+H]+ , 792 (100) [M(81Br)+H]+ ; HRMS (FTMS +p ESI): m/z
calculated for C32H41BrN9O10
+ [M(79Br+H)]+ : 790.2154; found:
790.2150.
Heck cross-coupling of Br-pacidamycin D to give 45
To a solution of the purified 7-Br-pacidamycin D (0.5 mg) in de-
gassed water-acetonitrile (3:1), sodium tetrachloropalladate
(10 mol%), TXPTS (23 mol%) (from stock solution in degassed
water-acetonitrile (3:1) 10 mm) were added followed by Na2CO3
(4 equiv) and 4-fluorostyrene (5 equiv) were added. The vial was
closed and the reaction mixture was stirred and heated at 90 8C
(MW) for 2 hour. After completion, the reaction was cooled down
to RT was diluted with water (10 mL) and acidified (pH=2–3) using
0.1m HCl. The resulting mixture was extracted with ethyl acetate
(310 mL). Complete conversion was observed by LC-HRMS analy-
sis of the crude reaction mixture. Attempted purification by HPLC
was not successful to isolate desired product, which may be due
to very low quantities of product 45.
MS (ESI): 832 (100) [M+H]+ ; HRMS (FTMS +p ESI): m/z calculated
for C40H47FN9O10
+ [M+H]+ : 832.3424; found: 832.3422.
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Heck Diversification of Indole-Based
Substrates under Aqueous Conditions:
From Indoles to Unprotected Halo-
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Natural Product Derivatives
Aqueous Heck cross-coupling of un-
protected halo-indoles and halo-trypto-
phans, showing broad reaction scope is
presented. We demonstrate application
of this methodology in the functionali-
sation of a brominated antibiotic
(bromo-pacidamycin) and a marine
sponge metabolite, barettin.
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